6-((4-nitrobenzyl)thio)-9H-purine | 5434-26-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 6-((4-nitrobenzyl)thio)-9H-purine
• 英文别名: 6-[(4-nitrophenyl)methylsulfanyl]-7H-purine
• CAS: 5434-26-4
• 化学式: C₁₂H₉N₅O₂S
• 分子量: 287.302
• InChiKey: UBRDHOJAHBCLCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  126
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  6-((4-nitrobenzyl)thio)-9H-purine 在 sodium hydride 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 23.08h， 生成 2-[6-(4-nitro-benzylsulfanyl)-purin-9-ylmethyl]-phenylamine
  参考文献：
  名称：

  Inhibition of Nucleoside Transport by New Analogues of 4-Nitrobenzylthioinosine:  Replacement of the Ribose Moiety by Substituted Benzyl Groups

  摘要：

  4-Nitrobenzylthioinosine (NBTI, 1) is a well-known inhibitor for the nucleoside transport protein ENT1. However, its highly polar nature is unfavorable for oral absorption and/or penetration into the CNS. In the search for compounds with lower polarity than NBTI we replaced its ribose moiety by substituted benzyl groups. Halogen, hydroxyl, (trifluoro)methyl(-oxy), nitro, and amine functionalities were among the substituents at the benzyl group. In general, substitution of the benzyl group resulted in a lower affinity for ENT1. Only 2-hydroxyl substitution showed a higher affinity. Most likely this is the result of hydrogen bonding. Substitution at the 2-position of the benzyl group with aryl groups was also addressed. Compared to parent compound carrying a 2-phenylbenzyl group, all synthesized analogues gave higher affinities. Introduction of fluoro, trifluoromethyl, methoxy, and hydroxyl groups at the phenyl group clearly showed that addition to the 4-position was preferable. Despite the highly different character of a ribose and a benzyl group, K-i values in the low nanomolar range were obtained for the benzyl-substituted derivatives. Compound 35, LUF5919, and compound 60, LUF5929, displayed the highest affinity (K-i = 39 nM for both compounds), having a polar surface area of 101 Angstrom(2) and 85 Angstrom(2), respectively.

  DOI：

  10.1021/jm049735v
• 作为产物：
  描述：

  对硝基溴化苄 、 6-mercaptopurine 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.08h， 以91%的产率得到6-((4-nitrobenzyl)thio)-9H-purine
  参考文献：
  名称：

  New analogs of nitrobenzylthioinosine

  摘要：

  这项发明涉及新的硝基苯基硫基核苷类似物或衍生物，以及利用这些新的硝基苯基硫基核苷类似物治疗疼痛和其他各种疾病，以及包含至少一种新的硝基苯基硫基核苷类似物的药品。

  公开号：

  EP1352910A1

文献信息

• Triptycene analogs
  申请人：——

  公开号：US20020091163A1

  公开（公告）日：2002-07-11

  This invention provides analogs of triptycene which are useful as anticancer drugs, as well as for other uses. The potency of these compounds is in a similar magnitude as daunomycin, a currently used anticancer drug. Each compound of the invention produces one or more desired effects (blocking nucleoside transport, inhibiting nucleic acid or protein syntheses, decreasing the proliferation and viability of cancer cells, inducing DNA fragmentation or retaining their effectiveness against multidrug-resistant tumor cells).

  这项发明提供了三苯乙烯的类似物，可用作抗癌药物，以及其他用途。这些化合物的效力与目前使用的抗癌药达诺霉素相当。该发明的每种化合物都产生一个或多个期望的效果（阻断核苷酸转运、抑制核酸或蛋白质合成、降低癌细胞的增殖和存活能力、诱导DNA断裂或保持其对多药耐药肿瘤细胞的有效性）。
• [EN] TRIPTYCENE ANALOGS<br/>[FR] ANALOGUES DE TRIPTYCÈNE
  申请人：UNIV KANSAS STATE

  公开号：WO2002028808A1

  公开（公告）日：2002-04-11

  This invention provides analogs of triptycene which are useful as anticancer drugs, as well as for other uses. The potency of these compounds is in a similar magnitude as daunomycin, a currently used anticancer drug. Each compound of the invention produces one or more desired effects (blocking nucleoside transport, inhibiting nucleic acid or protein syntheses, decreasing the proliferation and viability of cancer cells, inducing DNA fragmentation or retaining their effectiveness against multidrug-resistant tumor cells).

  本发明提供了三苯甲烷的类似物，可用作抗癌药物，以及其他用途。这些化合物的效力与目前使用的抗癌药物多柔比星相似。本发明的每个化合物都产生一个或多个期望的效果（阻止核苷酸转运，抑制核酸或蛋白质合成，减少癌细胞的增殖和生存能力，诱导DNA断裂或保持它们对多药耐药肿瘤细胞的有效性）。
• Analogs of nitrobenzylthioinosine
  申请人：Puetz Claudia

  公开号：US20050096293A1

  公开（公告）日：2005-05-05

  Analogs or derivatives of nitrobenzylthioinosine compounds. The use of these new analogs of nitrobenzylthioinosine and methods for the treatment of pain and various other indications using these analogs of nitrobenzylthioinosine as well as pharmaceutical compositions including analogs of nitrobenzylthioinosine.

  硝基苯基硫代核苷类似物或衍生物。使用这些新的硝基苯基硫代核苷类似物的方法，治疗疼痛和其他各种适应症，以及包括硝基苯基硫代核苷类似物的制药组合物。
• CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS
  申请人：Consejo Superior de Investigaciones Científicas (CSIC)

  公开号：EP3604310A1

  公开（公告）日：2020-02-05

  The present invention relates to a series of substituted purine derivatives capable of inhibiting CDC7 kinase activity and, as such, suitable for use in the treatment of neurological diseases such as, inter alia, Alzheimer's disease, amyotrophic lateral sclerosis or frontotemporal dementia, involving hyperphosphorylation of TDP-43 and the subsequent formation of aggregates, induced by CDC7.

  本发明涉及一系列能够抑制 CDC7 激酶活性的取代嘌呤衍生物，因此适用于治疗神经系统疾病，如阿尔茨海默病、肌萎缩侧索硬化症或额颞叶痴呆症等，这些疾病涉及 CDC7 诱导的 TDP-43 过度磷酸化及随后形成的聚集体。
• CDC-7-inhibitor compounds and use thereof for the treatment of neurological conditions
  申请人：CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

  公开号：US11446304B2

  公开（公告）日：2022-09-20

  The present invention relates to a series of substituted purine derivatives capable of inhibiting CDC7 kinase activity and, as such, suitable for use in the treatment of neurological diseases such as, inter alia, Alzheimer's disease, amyotrophic lateral sclerosis or frontotemporal dementia, involving hyperphosphorylation of TDP-43 and the subsequent formation of aggregates, induced by CDC7.

  本发明涉及一系列能够抑制 CDC7 激酶活性的取代嘌呤衍生物，因此适用于治疗神经系统疾病，如阿尔茨海默病、肌萎缩侧索硬化症或额颞叶痴呆症等，这些疾病涉及 CDC7 诱导的 TDP-43 过度磷酸化及随后形成的聚集体。